Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Novel Therapies for Metabolic Complications of Lipodystrophies
This study is currently recruiting participants.
Verified by University of Texas Southwestern Medical Center, April 2007
Sponsors and Collaborators: University of Texas Southwestern Medical Center
National Institutes of Health (NIH)
Takeda Global Research & Development Center, Inc.
Information provided by: University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT00457938
  Purpose

Lipodystrophies represent a therapeutic challenge with regards to the management of the diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present in conjunction with significant adipose tissue loss. The purpose of the study and it’s four subprojects is to examine the safety and efficacy of various novel interventions designed to improve or resolve the fatty liver, hypertriglyceridemia, and insulin resistance or diabetes that is seen in these patients.


Condition Intervention Phase
Insulin Resistance
Hypertriglyceridemia
Diabetes
Hepatic Steatosis
Drug: leptin
Drug: pioglitazone
Drug: cholic acid
Behavioral: low-fat diet
Phase II
Phase III

MedlinePlus related topics: Diabetes Triglycerides
Drug Information available for: Pioglitazone Pioglitazone hydrochloride Leptin Cholic acid
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title: Novel Therapies for Metabolic Complications in Patients With Lipodystrophies

Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c,

Estimated Enrollment: 72
Study Start Date: April 2006
Estimated Study Completion Date: August 2011
Detailed Description:

We propose novel therapeutic approaches for the management of metabolic complications in patients with lipodystrophies. The four interventions to be tested are:

Hypothesis 1: An extremely low fat diet. Hypothesis 2: Leptin replacement therapy. Hypothesis 3: Cholic acid therapy.. Hypothesis 4: Peroxisome proliferator activated receptors (PPAR)  agonist, pioglitazone.

  Eligibility

Ages Eligible for Study:   14 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General Inclusion criteria:

  • Patients with lipodystrophies as diagnosed by clinical criteria
  • Any one of the following:

    • Diabetes mellitus, or
    • Fasting serum triglycerides > 200 mg/dL, or
    • Fasting serum insulin > 30 U/mL, or
    • Hepatic steatosis (>5.6% hepatic triglyceride content) as demonstrated by 1H MRS.

Exclusion Criteria:

  • Known liver disease due to causes other than non-alcoholic steatohepatitis:
  • Current alcohol abuse (>7 drinks or 210 g per wk for women and >14 drinks or 420 g per wk for men).
  • Positive serological markers of hepatitis B and C.
  • Autoimmune hepatitis, autoimmune cholestatic liver disorders, Wilson disease and Alpha-1-antitrypsin deficiency as indicated by clinical and laboratory tests.
  • Drug-induced liver disease
  • Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml and/or liver mass on imaging study suggestive of liver cancer.
  • Decompensated liver disease as evidenced by clinical features of hepatic failure (variceal bleeding, ascites, hepatic encephalopathy etc.) and laboratory investigations (prolonged prothrombin time, hypoalbuminemia, presence of esophageal varices etc.)
  • Use of the drugs which can potentially decrease hepatic steatosis during previous 3 months; high-dose vitamin E, betaine, acetylcysteine, choline and probucol.
  • Significant systemic or major illnesses other than liver disease (congestive heart failure, unstable angina, cerebrovascular disease, respiratory failure, renal failure [serum creatinine >2 mg/dL], acute pancreatitis, organ transplantation, serious psychiatric disease, and malignancy) that could interfere with the trial and adequate follow up.
  • Acute medical illnesses precluding participation in the studies.
  • Known HIV infected patient.
  • Current substance abuse.
  • Pregnant or lactating women.
  • Hematocrit of less than 30%.
  • History of weight loss (>10%) or use of weight loss drugs such as sibutramine or orlistat in the last 3 months.

Each subproject has additional specific inclusion and exclusion criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00457938

Contacts
Contact: Claudia Quittner, RN, BSN, MS 214-648-9296 claudia.quittner@utsouthwestern.edu
Contact: Lalitha Subramnayam, MD 214-648-4773 lalitha.subramanyam@utsouthwestern.edu

Locations
United States, Texas
UT Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Claudia Quittner, RN, BSN, MS     214-648-9296     claudia.quittner@utsoutwestern.edu    
Contact: Lalitha Subramanyam, M.D.     214-648-4773     lalitha.subramanyam@utsouthwestern.edu    
Principal Investigator: Abhimanyu Garg, M.D.            
Sub-Investigator: Vinaya Simha, M.D.            
Sub-Investigator: Lalitha Subrammanyam, M.D.            
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Takeda Global Research & Development Center, Inc.
Investigators
Principal Investigator: Abhimanyu Garg, MD UT Southwestern Medical Center
  More Information

click here for more information about lipodystrophy  This link exits the ClinicalTrials.gov site

Study ID Numbers: RO1-074959, DK074959
Study First Received: April 4, 2007
Last Updated: April 6, 2007
ClinicalTrials.gov Identifier: NCT00457938  
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Texas Southwestern Medical Center:
lipodystrophy

Study placed in the following topic categories:
Liver Diseases
Hypertriglyceridemia
Hyperlipidemias
Metabolic Diseases
Pioglitazone
Skin Diseases
Diabetes Mellitus
Fatty Liver
Cholic Acids
Hyperinsulinism
Digestive System Diseases
Lipodystrophy
Insulin Resistance
Metabolic disorder
Glucose Metabolism Disorders
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Hypoglycemic Agents
Skin Diseases, Metabolic
Therapeutic Uses
Physiological Effects of Drugs
Gastrointestinal Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009